Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Added: 4 months ago Source:  Radcliffe Cardiology
For patients hospitalised with acute heart failure, receiving an influenza vaccination prior to discharge can significantly lower the risk of all-cause mortality and subsequent hospital readmission over the following year. These findings come from the PANDA II trial, a large cluster-randomised study conducted in China.¹PANDA II was a pragmatic, multiregional, parallel-group, cluster-randomised,… View more
Author(s): Raj Makkar Added: 2 months ago
TCT 25 - Dr Raj Makkar (Cedars-Sinai Medical Center, US) joins us to discuss the findings on the EVOQUE Valve (Edwards Lifesciences) drawing from data in the STS/ACC Transcatheter Valve Therapy Registry.The study evaluated procedural success rates, in-hospital complications, and 30-day clinical outcomes in patients undergoing transcatheter tricuspid valve replacement for severe tricuspid… View more
Research Area(s) / Expertise:

Intervention

Job title: Interventional Cardiologist and Director of Cardiovascular Research
DrAmod Amritphale is an interventional cardiologist and the Director of Cardiovascular Research at the University of South Alabama, AL, US. He is a pioneer and an authority in the use of artificial intelligence and machine learning models for predictive modelling and exploring core outcomes in cardiovascular disease.He is also extensively involved in research involving coronary artery disease,… View more
Author(s): Gilles Montalescot , Mathieu Kerneis Added: 2 years ago
ESC 23 - We are joined onsite by Dr Mathieu Kerneis (Pitie Salpetriere APHP University Hospital, FR) and Dr Gilles Montalescot to discuss the findings from the ARAMIS trial (NCT03018834). ARAMIS was the largest randomised controlled trial of acute myocarditis. The study included 120 hospitalised, symptomatic patients with increased cardiac troponin and diagnosed acute myocarditis using cardiac… View more
Author(s): Borja Ibanez Added: 4 months ago
ESC Congress 2025 - REBOOT-MI finds that beta-blocker therapy after MI did not reduce the occurrence of adverse events in patients with LVEF greater than 40%.Dr Borja Ibanez (National Centre for Cardiovascular Research, Madrid, ES) joins us to discuss findings from REBOOT-CNIC (NCT03596385). The prospective, randomised, open-label trial investigated the benefits of long-term betablocker therapy… View more